Linked-in: Design and efficacy of antibody drug conjugates in oncology

Jonathan Feld, Stefan K. Barta, Carolina Schinke, Ira Braunschweig, Yiyu Zhou, Amit K. Verma

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The use of antibody drug conjugates (ADCs) as targeted chemotherapies has successfully entered clinical practice and holds great promise. ADCs consist of an antibody and toxin-drug combined together via a chemical linker. While the antibody and drug are of vital importance in the direct elimination of cancer cells, more advanced linker technology was instrumental in the delivery of more potent drugs with fewer side effects. Here, we discuss the preclinical experience as well as clinical trials, with a specific emphasis on the clinical outcomes and side effects, in addition to linker strategies for five different ADCs, in order to describe different approaches in the development of this new class of anticancer agents. Brentuximab vedotin is approved for use in Hodgkin's lymphoma and Trastuzumab emtansine is approved for breast cancer. Combotox, Inotuzumab Ozogamicin, and Moxetumomab Pasudotox are in various stages of clinical development and are showing significant efficacy in lymphoid malignancies. These ADCs illustrate the promise and future potential of targeted therapy for presently incurable malignancies.

Original languageEnglish (US)
Pages (from-to)397-412
Number of pages16
JournalOncotarget
Volume4
Issue number3
StatePublished - Mar 2013

Fingerprint

Antibodies
Pharmaceutical Preparations
Immunotoxins
Neoplasms
Hodgkin Disease
Antineoplastic Agents
Clinical Trials
Breast Neoplasms
Technology
Drug Therapy
Therapeutics

Keywords

  • Antibody drug conjugates
  • Immunotoxins
  • Oncotargets

ASJC Scopus subject areas

  • Oncology

Cite this

Linked-in : Design and efficacy of antibody drug conjugates in oncology. / Feld, Jonathan; Barta, Stefan K.; Schinke, Carolina; Braunschweig, Ira; Zhou, Yiyu; Verma, Amit K.

In: Oncotarget, Vol. 4, No. 3, 03.2013, p. 397-412.

Research output: Contribution to journalArticle

Feld, J, Barta, SK, Schinke, C, Braunschweig, I, Zhou, Y & Verma, AK 2013, 'Linked-in: Design and efficacy of antibody drug conjugates in oncology', Oncotarget, vol. 4, no. 3, pp. 397-412.
Feld, Jonathan ; Barta, Stefan K. ; Schinke, Carolina ; Braunschweig, Ira ; Zhou, Yiyu ; Verma, Amit K. / Linked-in : Design and efficacy of antibody drug conjugates in oncology. In: Oncotarget. 2013 ; Vol. 4, No. 3. pp. 397-412.
@article{2110099cbcd443ffa8a6bc894abd3691,
title = "Linked-in: Design and efficacy of antibody drug conjugates in oncology",
abstract = "The use of antibody drug conjugates (ADCs) as targeted chemotherapies has successfully entered clinical practice and holds great promise. ADCs consist of an antibody and toxin-drug combined together via a chemical linker. While the antibody and drug are of vital importance in the direct elimination of cancer cells, more advanced linker technology was instrumental in the delivery of more potent drugs with fewer side effects. Here, we discuss the preclinical experience as well as clinical trials, with a specific emphasis on the clinical outcomes and side effects, in addition to linker strategies for five different ADCs, in order to describe different approaches in the development of this new class of anticancer agents. Brentuximab vedotin is approved for use in Hodgkin's lymphoma and Trastuzumab emtansine is approved for breast cancer. Combotox, Inotuzumab Ozogamicin, and Moxetumomab Pasudotox are in various stages of clinical development and are showing significant efficacy in lymphoid malignancies. These ADCs illustrate the promise and future potential of targeted therapy for presently incurable malignancies.",
keywords = "Antibody drug conjugates, Immunotoxins, Oncotargets",
author = "Jonathan Feld and Barta, {Stefan K.} and Carolina Schinke and Ira Braunschweig and Yiyu Zhou and Verma, {Amit K.}",
year = "2013",
month = "3",
language = "English (US)",
volume = "4",
pages = "397--412",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "3",

}

TY - JOUR

T1 - Linked-in

T2 - Design and efficacy of antibody drug conjugates in oncology

AU - Feld, Jonathan

AU - Barta, Stefan K.

AU - Schinke, Carolina

AU - Braunschweig, Ira

AU - Zhou, Yiyu

AU - Verma, Amit K.

PY - 2013/3

Y1 - 2013/3

N2 - The use of antibody drug conjugates (ADCs) as targeted chemotherapies has successfully entered clinical practice and holds great promise. ADCs consist of an antibody and toxin-drug combined together via a chemical linker. While the antibody and drug are of vital importance in the direct elimination of cancer cells, more advanced linker technology was instrumental in the delivery of more potent drugs with fewer side effects. Here, we discuss the preclinical experience as well as clinical trials, with a specific emphasis on the clinical outcomes and side effects, in addition to linker strategies for five different ADCs, in order to describe different approaches in the development of this new class of anticancer agents. Brentuximab vedotin is approved for use in Hodgkin's lymphoma and Trastuzumab emtansine is approved for breast cancer. Combotox, Inotuzumab Ozogamicin, and Moxetumomab Pasudotox are in various stages of clinical development and are showing significant efficacy in lymphoid malignancies. These ADCs illustrate the promise and future potential of targeted therapy for presently incurable malignancies.

AB - The use of antibody drug conjugates (ADCs) as targeted chemotherapies has successfully entered clinical practice and holds great promise. ADCs consist of an antibody and toxin-drug combined together via a chemical linker. While the antibody and drug are of vital importance in the direct elimination of cancer cells, more advanced linker technology was instrumental in the delivery of more potent drugs with fewer side effects. Here, we discuss the preclinical experience as well as clinical trials, with a specific emphasis on the clinical outcomes and side effects, in addition to linker strategies for five different ADCs, in order to describe different approaches in the development of this new class of anticancer agents. Brentuximab vedotin is approved for use in Hodgkin's lymphoma and Trastuzumab emtansine is approved for breast cancer. Combotox, Inotuzumab Ozogamicin, and Moxetumomab Pasudotox are in various stages of clinical development and are showing significant efficacy in lymphoid malignancies. These ADCs illustrate the promise and future potential of targeted therapy for presently incurable malignancies.

KW - Antibody drug conjugates

KW - Immunotoxins

KW - Oncotargets

UR - http://www.scopus.com/inward/record.url?scp=84879007299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879007299&partnerID=8YFLogxK

M3 - Article

C2 - 23651630

AN - SCOPUS:84879007299

VL - 4

SP - 397

EP - 412

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 3

ER -